---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000046"
form_type: "8-K/A"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:10:17.233104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed

## Summary
- Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.
- Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.
- VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.
- VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.
- Appointed Dr. Leon Hooftman as CMO effective June 3, 2024.

## SEC filing metadata
- accession: 0001828185-24-000046
- form_type: 8-K/A
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/0001828185-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/brns-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000046
- JSON: https://secwatch.observer/filing/0001828185-24-000046.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000046.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported first quarter of 2024 results: revenue nil.
  - Period: first quarter of 2024
  - Revenue: nil
  - Result: reported results
  source text: On May 13, 2024, the Company announced its financial results for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000046/0001828185-24-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.